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Vikas Kumar1*, Danish Ahmed1, Firoz Anwar2, Mohammed Ali3 and Mohd Mujeeb3*Abstract
Objective: The objective of the present study was to evaluate the effect of umbelliferon-α-D-glucopyranosyl-
(2I→ 1II)-α-D-glucopyranoside (UFD) from Aegle marmelos Corr. on serum glucose, lipid profile and free radical
scavenging activity in normal and STZ (streptozotocin) induced diabetic rats.
Materials and methods: Diabetes was induced by single interperitoneal injecting of streptozotocin (60 mg/kg, i.p.)
in the rats. All the rats were divided into following groups; I - nondiabeteic, II - nondiabetic + UFD (40 mg/kg, p.o.),
III - diabetic control, IV - UFD (10 mg/kg, p.o.), V - UFD (20 mg/kg, p.o.), VI - UFD (40 mg/kg) and VII - glibenclamide
(10 mg/kg, p.o.). Serum glucose level and body weight were determined periodically. Biochemical parameter,
antioxidant enzyme and histopathology study were performed on the day 28. Oral glucose tolerance test study
was performed to identify the glucose utilization capacity.
Results: All the doses of UFD and glibenclamide decrease the level of serum glucose, glycated hemoglobin,
glucose-6-phosphatase, fructose-1-6-biphosphate and increased the level of plasma insulin, hexokinase. The UFD
doses also showed effects on antioxidant enzymes viz. superoxide dismutase, catalase and glutathione peroxidase
which were significantly increased and the level of malonaldehyde was markedly decreased. Histologically study,
focal necrosis, deposition of fats, increased the size of the intercalated disc were observed in the diabetic rat liver,
kidney, heart and pancreas but was less obvious in treated groups. The mechanism of action of the UFD emerges
to be due to increase the activity of antioxidant enzyme and secretion of pancreatic insulin.
Conclusion: Reduction in the FBG (fasting blood glucose), glycated hemoglobin, glucose-6-phosphatase,
fructose-1-6-biphosphate, superoxide dismutase, catalase, glutathione peroxides, cholesterol, triglyceride, LDL,
VLDL levels and improvement in the level of the plasma insulin, hexokinase, HDL was observed by the UFD
treated rats. The result indicates that UFD has anti-diabetic activity along with anti hyperlipidemic and antioxidant
efficacy and provides a scientific rationale to be used as an Anti-diabetic agent.
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Figure 1 Structure of UFD.
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Diabetes mellitus (DM) is a group of syndrome character-
ized by dietary intake, changing in the lifestyle, excessive
use of lipid, carbohydrate and protein. Poorly controlled
blood glucose level is the major factor in the developmentTable 1 13C NMR spectral data for compounds BG II (UFD)























Coupling constants in Hertz are provided in parenthesis.of both diabetic complication such as type 1 diabetes
and type 2 diabetes (American Association of Diabetes
Educators 2002). STZ is mainly used for induction of
experimental autoimmune diabetes. Low dose administra-
tion of STZ in the peritoneal cavity of an animal is the best
model for type I diabetes. Oral hypoglycaemic agents
(insulin, sulphonylureas, thiazolidiones and bioguanides)
and different plant based drugs were used for the treatment
of diabetes, but oral hypoglycaemic drug having some
limitation in the treatment of diabetes (Valiathan 1998).
The plants based drugs are gaining popularity day by day.
These plant based drugs possess active ingredient and act
on variety of targets by various mode and mechanism.
Several species of plants have been reported in the
reputed alternative system of medicine as best choice
for the treatment of diabetes because plant based
antidiabetic drug are considered less toxic and free from
side effects. The major drawback of the natural therapy is
limitation of bioactive compound for claiming their antidia-
betic effect (Morin 1987). Most of the researchers claimed
that diabetes complications were occurred by oxidative
stress (Halliwell and Gutteridge 1989). Clinical and
experimental condition of diabetes increasing the level
of oxidative stress otherwise changes in antioxidant
capacity and produced the etiology of chronic diabetes
(Ravi et al. 2004). Coumarins widely consumed in the
human diet in the form of vegetable and fruits (Hoult
and Paya 1996), coumarins present in the food and
vegetable play an important role as dietary antioxidants.
Many investigator claim that several phenolic coumarins
might play a role as dietary antioxidants, because several
fruit and vegetable were consumed by human beings
as food.
Aegle marmelos Corr. (Rutaceae) is a very common
plant found especially in hills of the Himalaya, dry forest and




0 30 60 90 120 150
1 Glucose Control 81.6 ± 1.208 154.6 ± 1.965 143.8 ± 1.158 133.2 ± 1.463 120.2 ± 1.655 110.6 ± 1.435
2 UFD (10 mg/kg) 82.4 ± 1.435 140 ± 1.517 133 ± 0.836 126.2 ± 2.289 111.4 ± 0.923 99.8 ± 0.861
3 UFD (20 mg/kg) 81.6 ± 1.077ns 130.4 ± 1.991ns 121 ± 1.817* 112 ± 1.517** 97.4 ± 0.927*** 84.6 ± 1.536***
4 UFD (40 mg/kg) 82.2 ± 1.881ns 121.4 ± 1.503** 112 ± 1.517*** 99.6 ± 1.208*** 82 ± 2.001*** 62.6 ± 1.327***
5 Glibenclamide (10 mg/kg) 81 ± 1.581ns 125 ± 0.707** 116.4 ± 0.509** 103 ± 0.717*** 85.8 ± 1.158*** 69.6 ± 1.248***
All values represent mean ± SEM *P < 0.05; **P < 0.01; ***P < 0.001, ns < non significant; ANOVA, followed by Dunnett’s multiple comparison test.
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Gupta and Tandon 2004). Different parts (leaves, fruit, bark
and stem) of the plant are used as ethanomedicine
against fevers, abdomen pain, palpitation of the heart,
urinary troubles, melancholia, anorexia, dyspepsia, diabetes
and diarrhea (Badam et al. 2004; Gupta and Tandon 2004).
More than 100 chemical constituent were isolated from the
Aegle marmelos Correa including eugenol, lupeol, aegeline,
marmasinin, marmin, skimmianine, aegelin, lupeol, cineole,
citral, citronellal, cuminaldehyde (4-isopropylbenzaldehyde),
eugenol, marmesinin, marmelosin, luvangetin, aurapten,
psoralen, marmelide, fagarine, and tannins. These chemical
constituents have been proved active against various disease
like malaria, gastrointestinal and cancer disease. Different
solvent extracts showed effectiveness against antiulcer,
antidiabetic, antioxidant, antihyperlipidemic, antipyretic, anti-
inflammatory on various models of animal. But the bioactive
compound present in this extract was not identified in their
natural process. Presently, there is no published source for
the claim about the antidiabetic, antihyperlipidemic and anti-
oxidant activities of bioactive compounds isolated from A.
marmelos (Litchfield and Wilcoxon 1949; Maity et al. 2009).
Umbelliferon-α-D-glucopyranosyl-(2I→ 1II)-α-D-glucopyra-
noside (shown in Figure 1), a glucosidic derivative of couma-
rin (6-hydroxycoumarin), isolated from the stem bark of A.
marmelos is powerful antioxidant. The present study investi-


























Figure 2 Effect of UFD on fasting plasma glucose on oral glucose tole
rats, compared to standard drug Glibenclamide; values are mean ± SE
as non-significant (ns).compound, umbelliferon-α-D-glucopyranosyl-(2I→ 1II)-
α-D-glucopyranoside on antidiabetic, antihyperlipidemic
and antioxidant effect on STZ-induced diabetic rats.Material and methods
General
Veego, Model No. MPI melting point apparatus was
used for melting point. 1H NMR spectra were recorded
on Bruker Advance II 400 NMR Spectrophotometer
and 13C NMR spectra on Bruker Advance II 100 NMR
Spectrophotometer in DMSO using TMS as internal stand-
ard. Mass spectra were obtained on the VG-AUTOSPEC
spectrometer. UV λmax (DMSO) were recorded on
Shimadzu UV-1700 and FT-IR (in 2.0 cm-1, flat,
smooth, Abex) were taken on Perkin Elmer – Spectrum
RX-I spectrophotometer.Chemical
Streptozotocin (Sigma Chemical Co. USA), GOD/POD kit,
Cholesterol kit, Triglyceride kit, (Span, India), Glibenclamide
(Ranbaxy, India), Carboxyl methyl cellulose (CMC) (SD fine,
India) were purchased from respective vendor. Silica gel
(60–120 mesh) (Nicholas India Pvt. Ltd) was used for
column chromatography. The entire reagent utilized for
experimental protocol and chromatographic isolation were
of analytical grade and used without further purification.0 150
OGTT (mg/dL), Gp I, Normal
Control
OGTT (mg/dL), Gp II, UFD I (10
mg/kg)
OGTT (mg/dL), Gp III,UFD (20
mg/kg)
OGTT (mg/dL), Gp VI, UFD III (40
mg/kg)







rance test at different concentrations on STZ induced diabetic
M; n = 6; *P < 0.05; **P < 0.01; ***P < 0.001; P > 0.05 is considered
Table 3 Effect of UFD on biochemical parameter in STZ induced diabetic rats
S. No. Biochemical parameter Normal
control




STZ diabetes + UFD
(10 mg/kg)b
STZ diabetes + UFD
(20 mg/kg)b
STZ diabetes + UFD
(40 mg/kg)b
STZ diabetes + Glibenclamide
(10 mg/kg)b
1 Fasting plasma glucose (mg/dL) 83.4 ± 0.509 81.40 ± 0.748 432.4 ± 4.251*** 174.4 ± 3.945*** 143 ± 3.082*** 107.4 ± 2.731*** 117.2 ± 2.764***
2 Fasting plasma insulin (μU/mL) 12 ± 0.701 11.8 ± 0.832 2.2 ± 0.374*** 4.4 ± 0.509* 7.2 ± 0.374** 10.4 ± 0.519*** 10.2 ± 0.374***
3 Glycated heamoglobin (A1c) (%) 1.3 ± 0.071 1.3 ± 0.082 4.52 ± 0.107*** 3.9 ± 0.172* 3.2 ± 0.078** 2.34 ± 0.093*** 2.56 ± 0.075***
4 Total cholesterol (mg/dl) 65.8 ± 1.281 65.8 ± 0.969 156.6 ± 3.415*** 101.6 ± 1.375* 82 ± 0.7071** 68.4 ± 1.691*** 72.4 ± 1.364***
5 Triglycerides (mg/dl) 83 ± 1.732 83.6 ± 1.412 156.8 ± 4.247*** 116.4 ± 1.721* 109.2 ± 1.801** 91.6 ± 2.315*** 95.8 ± 2.354***
6 HDL cholesterol (mg/dl) 54.8 ± 2.417 55.4 ± 1.536 26.6 ± 1.364*** 37 ± 1.304* 42.8 ± 1.715** 53.2 ± 1.463*** 50.6 ± 1.077***
7 LDL cholesterol (mg/dl) 11.40 ± 0.245 10 ± 0.316 151.6 ± 0.509*** 74.8 ± 0.374* 49 ± 0.316** 21.4 ± 1.913*** 27 ± 0.316***
8 VLDL cholesterol (mg/dl) 16.6 ± 0.346 16.72 ± 0.281 31.36 ± 0.849*** 23.28 ± 0.344* 21.84 ± 0.361** 18.32 ± 0.463*** 19.16 ± 0.471***
9 Hexokinase (μg/mg of tissue) 147.2 ± 2.498 147 ± 2.302 96 ± 2.429*** 112 ± 1.141* 128.6 ± 3.251** 141.4 ± 1.913*** 137.4 ± 1.327***
10 Glucose-6-phosphatase
(unit/mg of tissue)
9.2 ± 0.583 9.2 ± 0.583 14.2 ± .582*** 13.6 ± 0.401ns 11.4 ± 0.509* 9.8 ± 0.374*** 10.8 ± .372***
11 Fructose-1-6-biphosphatase
(unit/mg of tissue)
29.6 ± 0.927 29.80 ± 0.969 55.6 ± 1.077*** 45.4 ± 0.927* 35 ± 0.707** 25.6 ± 0.509*** 29 ± 0.707***
12 Weight variation (g) 202.2 ± 1.021 206.2 ± 2.035 155.6 ± 3.011*** 193.8 ± 2.267*** 199.4 ± 1.435*** 203.4 ± 1.778*** 200.4 ± 1.722***
All values represent mean ± SEM *P < 0.05; **P < 0.01; ***P < 0.001, ns < non significant; ANOVA, followed by Dunnett’s multiple comparison test.
a Compared to vehicle control.
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The stem bark of Aegle marmelos Correa. was collected
from the Botanical Garden, Department of Pharmaceutical
Sciences, Faculty of Health Sciences, Sam Higginbottom
Institute of Agriculture, Technology & Sciences – Deemed
University, Allahabad, Uttar Pradesh, India and authenti-
cated by Dr. Imran Kajmi (Pharmacognosist). A specimen
voucher (SIP/HD/054/12) of the plant sample respectively
had been deposited in the herbarium of Siddharatha
Institute of Pharmacy, Dehradun, Uttarakhand, India.Extraction and isolation
The shade dry stem bark of Aegle marmelos Correa (2 kg)
was extracted with methanol (5 L) at 45°C for 72 hr. After
extraction total filtrate was concentrated to dryness in
rotatory vacuum evaporator at 40°C to obtain uniform slurry
(322 gm) (Kumar et al. 2009; Kumar et al. 2011a; Kumar
et al. 2013a). The slurry was dissolved in small amount of
methanol and absorbed on silica gel (60–120 mesh). It is
subjected to column using as a C6H14/CHCl3/MeOH
gradient system (1:0:0, 2:0:0, 4:0:0, 4:1:0, 1:1:0, 1:4:0,
1:6:0, 0:1:0, 0:48:0, 0:24:1, 0:48:2, 0:10:0, 0:10:1, 0:24:7,
and 0:47:10; 3.0 L for each gradient system), yielding
22 fractions. The collected fractions spotted on pre
coated silica gel TLC plate and the fractions having
the same Rf value pooled together in 7 fractions.
Fraction 8–14 (13.5 g) were combined separated on a silica
gel column (CHCl3/MeOH, 30:1), and rechromatographed
on a silica gel column (CHCl3/MeOH, 8:1), yielding 3
subtractions. Compound was separated by a normal phase
silica gel column (CHCl3/MeOH, 1:4). The compound
was found to be 100% pure by HPTLC by using solvent
system CHCl3/MeOH (20:1), see Figure 1.Drugs solution
UFD and glibenclamide were emulsified with 2% carboxyl



























Figure 3 Effect of UFD on fasting plasma glucose at different concen
Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP <Streptozotocin was dissolved in freshly prepared citrate
buffer (pH = 4. 5).
Animals
Male albino rat (Wistar strain 150-200 g) was used for
the experiment. The animals were housed under standard
conditions of temperature (25 ± 1°C), relative humidity
(55 ± 10%), 12 hr/12 hour light/dark cycles and fed on
standard pellet diet (Lipton rat feed, Ltd., Pune) and water
ad libitum. The experimental protocol was approved by
the Institutional Animal Ethical Committee of Siddhartha
Institute of Pharmacy (1435/PO/a/11/CPCSEA).
Acute toxicity study
The toxicity studies were adopted as per OESD Guideline
No.420; (Annexure-2d) of CPCSEA. For acute toxicity
studies in normal healthy rats fasted overnight and ran-
domly divided into five groups and each group contain rats
(n = 10). Rats were treated with starting doses (0.05, 0.10,
0.50 and 0.100 g/kg body weight) of test compound
and the control group was treated with vehicle alone
(CMC 2%; 1 ml/kg body weight). All the animal groups
allowed for food and water ad libitum and were
followed over a period of 2 h for changing in various
economical (Defecation and urination), neurological
(Spontaneous activities, reactivity, touch response, pain
response and gait) and behavior (Alertness, restlessness,
irritability, and fearfulness) responses (Litchfield and
Wilcoxon 1949; Lipnick et al. 1995). The mortality caused
by the extract within this period of the time was observed.
Assessment of compound in an oral glucose tolerance
test (Bonner-weir 1988)
Healthy rats were divided into five groups of six animals
each,
Group I (Control): treated with vehicle only.
Group II (UFD): treated with compound 10 mg/kg.Normal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
trations on STZ induced diabetic rats, compared to standard drug







Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)

















Figure 4 Effect of UFD on body weight at different concentrations on STZ induced diabetic rats, compared to standard drug
Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as non-significant (ns).
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Group IV (UFD): treated with compound 40 mg/kg.
Group V (Standard): treated with glibenclamide
10 mg/kg.
All group animals received drug and vehicle orally.
After 30 min treatment with different doses of UFD and
glibenclamide, all groups rat received 2 gm/kg of glucose.
The blood sample collected from the retro-orbit of the eye
of rats at regular interval of 0, 30, 60, 90, 120 and 150 min
each for their glucose tolerance.Induction of diabetes
Diabetes was induced in the Wistar rats by using the single
interperitoneal injection of streptozotocin (60 mg/kg body
weight). Volume of (STZ) 1 ml/kg body weight prepared
by STZ dissolving in freshly prepared 0.01 M citrate
buffer (pH = 4.5) (Brosky and Logothelopoulos 1969;
Ahmed et al. 2013). After 3 day of STZ administration,
blood glucose level of rats was estimated. Rats with a





















Figure 5 Effect of UFD on level of plasma insulin at different concent
Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP <Experimental design and schedule
The rats were randomly divided into 7 groups and each
group contains 6 animals.
Group I (Normal Control): Untreated group
Group II (Normal Control): UFD 40 mg/kg
Group III (Diabetic Control): Untreated group
Group IV: treated with compound UFD 10 mg/kg
Group V: treated with compound UFD 20 mg/kg
Group VI: treated with compound UFD 40 mg/kg
Group VII: treated with glibenclamide 10 mg/kg.
The treatment continued for 28 days by administration
of different doses of UFD and glibenclamide suspended
in 0.2% CMC once daily (Nicholas 1956). The fasting
blood glucose level was determined day 0, 5, 10, 15, 20,
25 and 28th day. During the experiment period change
in the body weight of rat was also recorded.Estimation of biochemical parameter
The blood samples were withdrawn on the day 28 collected
from a retro orbital puncture technique by capillary tubesNormal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
rations on STZ induced diabetic rats, compared to standard drug







Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)



























Figure 6 Effect of UFD on level of glycated hemoglobin (A1c) (%) at different concentrations on STZ induced diabetic rats, compared
to standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
Kumar et al. SpringerPlus 2013, 2:639 Page 7 of 20
http://www.springerplus.com/content/2/1/639containing anticoagulant (disodium ethylene diamine
tetra acetate) under mild anesthesia; blood was centrifuged
and examined for plasma glucose analysis was done by a
GOD - POD method using the Glucose Estimation Kit
(Span Diagnostic, India). Other serum estimation was done
spectrophotometrically using standard kits which
include total cholesterol, HDL and triglyceride (Span
Diagnostic, India). Plasma insulin was estimated by
the method of reported method of (Nicholas 1956).
For determination of the antioxidant enzyme, liver
was homogenized in ice chilled 10% potassium chloride
solution for estimating different parameters viz. super-
oxide dismutase (SOD), catalase (CAT), glutathione
peroxidase (GPx) and malonaldehyde (MDA) (Sinha 1972;
Rotruck et al. 1973; Kakkar et al. 1984).Histopathology
For histopathology study, after 28 days all group animals
were sacrificed under mild anesthesia and different organs
(heart, liver, pancreas and liver) were isolated for




























Figure 7 Effect of UFD on level of Hexokinase at different concentrat
Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP <fixed at 10% natural buffered formalin, dehydrated by
passing through a graded series of alcohol, and embedded
in paraffin blocks and 5 mm section was prepared using a
semi-automated rotatory microtome. Hematoxylin and
eosin were used for staining.Results
Compound identification
The methanolic extract of dried stem bark powder of
A. marmelos was subjected to column chromatography.
Chromatographically identical fractions (having the same Rf
values) were mixed together and concentrated. Collected
fractions were further purified by silica gel recolumn
chromatography to isolate compound ‘BG II’ (500 mg).
ESI-MS at m/z (rel. int.): 486 [M] + C21H26O13 (2.2),
1H
NMR (DMSO-d6): Table 1;
13C NMR (DMSO-d6): Table 1;
IR λmax (KBr): 3452, 3401, 3325, 2929, 2848, 1702, 1629,
1515, 1457, 1384, 1270, 1118, 1051 cm-1, UV λmax 256,
277, 332 nm (log ε 4.1, 5.8, 3.1) (Additional file 1: Spectral
Data of umbelliferon-α-D-glucopyranosyl-(2I→ 1II)-α-D-
glucopyranoside).Normal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
ions on STZ induced diabetic rats, compared to standard drug






Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)

































Figure 8 Effect of UFD on level of Glucose-6-phosphatase at different concentrations on STZ induced diabetic rats, compared to
standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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Acute toxicity studies exposed the non-toxic nature of
the isolated compound UFD. During the acute toxicity
study of the UFD on Wistar rats no mortality and no
change in the behavior were observed at end of the
study. There was no lethality or toxicity found at any
selected doses until the end of the study.Effect of UFD on oral glucose tolerance test
The oral glucose tolerance test was evaluated in
overnight fasted rats. The effect of different doses of
UFD on oral glucose tolerance presented in the
Table 2. The starting glucose level of the overnight
fasting rat was 81.6 mg/dl. Wistar rats after treated
with glucose the levels of blood glucose increased
were observed. Treatment was initiated with different
doses of UFD and glibenclamide significantly reduced







































Figure 9 Effect of UFD on level of Fructose1-6-biphosphate at differe
standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05
non-significant (ns).normal control group rat (Figure 2). Significantly, diminish-
ing level of blood glucose was observed with UFD
dose 10 mg/kg (28.71%), UFD 20 mg/kg (35.12%), UFD
40 mg/kg (48.43%) and glibenclamide 10 mg/kg (44.32%).Effect of UFD on blood sugar level
Administration of STZ produced the diabetes, thereby
increase the blood sugar level. The blood glucose level
of normal control group rats was 83.4 mg/dl. In the STZ
diabetic rats, the level of blood glucose reached to 432.2
mg/dl at day 28. STZ induced diabetic rats treated with
different doses of the UFD and glibenclamide showed
the significantly lowered the blood glucose level till 28
days. Selected doses of UFD 10, 20 and 40 mg/kg and
glibenclamide 10 mg/kg lowered the blood glucose level
by 40.84%, 52.33%, 63.45% and 60.45% respectively, thus
showing a significant decrease in blood glucose level
(Table 3, Figure 3).Normal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
nt concentrations on STZ induced diabetic rats, compared to






Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)





















Figure 10 Effect of UFD on level of total cholesterol at different concentrations on STZ induced diabetic rats, compared to
standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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The initial body weight was similar in non diabetic as
well as diabetic control groups. The administration of
different doses of UFD and glibenclamide treated group
significantly (P < 0.001) prevented decrease in body
weight (Table 3, Figure 4).Effect of UFD on plasma insulin level
The serum insulin level significantly decreased in STZ
induced diabetic control group rats was observed.
Three different doses of UFD (10, 20 and 40 mg/kg)
and glibenclamide (10 mg/kg) treated group rats
showed significant (P < 0.001) increase in the pancreatic
insulin compared to diabetic control group rats on day 28
(Table 3, Figure 5).Effect of UFD on the level of glycated hemoglobin
The level of glycated hemoglobin was increased in diabetic
group rats. Three different doses of UFD (10, 20 and
40 mg/kg) and glibenclamide (10 mg/kg) treated group




















Figure 11 Effect of UFD on level of triglyceride at different conce
standard drug Glibenclamide; values are mean ± SEM; n = 6; cP <
non-significant (ns).glycated hemoglobin compared to diabetic control groups
rats on day 28 was observed (Table 3, Figure 6).
Effect of UFD on the level of hexokinase
The level of the hexokinase was decreased in STZ
induced diabetic rats. Three different doses of UFD
(10, 20 and 40 mg/kg) and glibenclamide (10 mg/kg)
treated group rats, significantly (P < 0.001) increasing
the level of hexokinase compared to diabetic control
groups rats on day 28 (Table 3, Figure 7). The level of
hexokinase at UFD doses 40 mg/kg was a maximum
intensification at compared to other group received
different doses of UFD and glibenclamide.
Effect of UFD on the levels of glucose-6-phosphatase
In the STZ induced diabetic rats increased the level
of glucose-6-phosphate. Three different doses of UFD
(10, 20 and 40 mg/kg) and glibenclamide (10 mg/kg)
treated groups rats, significantly (P < 0.001) decreased
the level of glucose-6-phosphate compared to diabetic
control groups rats on day 28 (Table 3, Figure 8). An
UFD dose 40 mg/kg was more effective dose as comparedNormal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
ntrations on STZ induced diabetic rats, compared to






Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)






















Figure 12 Effect of UFD on level of HDL (High density lipoprotein) cholesterol at different concentrations on STZ induced diabetic rats,
compared to standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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tration groups.
Effect of UFD on the levels of fructose-1-6-biphosphatase
To evaluate the effect of different doses of UFD on distressed
hepatic activity, we administered UFD to STZ induced
diabetic rats. The level of fructose-1-6-biphosphate was
reached higher in diabetic rats. The administration of
different doses of UFD (10, 20 and 40 mg/kg) and
glibenclamide (10 mg/kg) treated groups rats significantly
(P < 0.001) declining the level of fructose-1-6-biphosphatse
(Table 3, Figure 9).
Effect of UFD on the level of total cholesterol
The level of cholesterol was increased in the STZ induced
diabetic rats. The administration of different doses of
UFD significantly decreased the level of total cholesterol
(Table 3, Figure 10).
Effect of UFD on the levels of serum triglycerides
It is evident from the figure that the administrations of























Figure 13 Effect of UFD on level of LDL (Low density lipoprotein) cho
compared to standard drug Glibenclamide; values are mean ± SEM; n
non-significant (ns).serum triglyceride level. The administration of different
doses of UFD the level of serum triglyceride subordinate
to a good extent. The maximum lowering the serum
triglyceride was appeared in the group received UFD
at a dose (40 mg/kg) (Table 3, Figure 11).Effect of UFD on the level of HDL cholesterol
It is predictable that the level of HDL cholesterol was
decreased in the STZ diabetic rats. Upon the administration
of different doses of UFD, significant increase in the level of
HDL cholesterol as compared to the diabetic rats (Table 3,
Figure 12).Effect of UFD on the level of LDL cholesterol
It is evident from the Figure 13 that STZ induced
diabetic rat showed an increase in level of LDL chol-
esterol. Treatment with different doses of UFD de-
creases the level of LDL cholesterol. The figure
suggests that maximum decrease in the higher level
of LDL cholesterol was found in UFD (40 mg/kg)
dose (Table 3).Normal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
lesterol at different concentrations on STZ induced diabetic rats,






Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)






















Figure 14 Effect of UFD on level of VLDL (Very low density lipoprotein) cholesterol at different concentrations on STZ induced diabetic
rats, compared to standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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http://www.springerplus.com/content/2/1/639Effect of UFD on the level of VLDL cholesterol
STZ induced diabetic rat clearly depicted the increased
level of VLDL cholesterol (Table 3). Oral administration
of different doses of UFD and glibenclamide significantly
(P < 0.001) decreases the level of VLDL cholesterol.
The Figure 14 suggests that UFD (40 mg/kg) dose
was more effective in decreasing the elevated level of
VLDL cholesterol.Effect of UFD on enzymatic antioxidant markers
Affect on enzymatic antioxidant markers, the level of
superoxidase dismutase (SOD), glutathione peroxidase
(GPx) and catalase (CAT) were increased and the level
of malondialdehyde (MDA) was significantly decreased
in STZ induced diabetic groups rat. Treatment with the
different doses of UFD (10, 20 and 40 mg/kg) and
glibenclamide (10 mg/kg) treated group rats significantly
(P < 0.001) increased the level of SOD (Figure 15), GPx
(Figure 16), CAT (Figure 17) and decreased the level of
























Figure 15 Effect of UFD on level of SOD (Superoxide dismutase) chol
compared to standard drug Glibenclamide; values are mean ± SEM; n
non-significant (ns).Effect of UFD on liver histopathology
Histopathology studies of the STZ induced diabetic rat
showed increased level of fat accumulation and large
area of hepatocytes taken over by fat droplet (Figure 19).
Oral administration of UFD with different doses improved
the kidney histopathology. UFD dose (10 mg/kg) showed
deposition of fat as compared to the normal rat, UFD
dose 20 mg/kg histopathology showed few macro droplets
of fat and UFD dose 40 mg/kg shown no fat depos-
ition as shown in the liver histopathology. Glibenclamide
treated group rat histopathology had shown normal liver
(Figure 20).
Effect of UFD on kidney histopathology
Histopathology of STZ induced diabetic rat kidney shows
inflammation in blood vessels, fat deposition, changes in
size of glomerulus and increases the thickness of bowman
capsules. Oral treatment with different doses of UFD
and glibenclamide showed the changes in STZ induced
diabetic groups rat. Different doses of UFD showing less
fat deposition, normal size of glomerulus and bowmanNormal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
esterol at different concentrations on STZ induced diabetic rats,





Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)




















Figure 16 Effect of UFD on level of CAT (Catalase) cholesterol at different concentrations on STZ induced diabetic rats, compared to
standard drug Glibenclamide; values are mean ± SEM; n = 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
non-significant (ns).
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dose showed normal histopathology of the kidney as
compared to the normal control (Figures 21 and 22).
Effect of UFD on pancreas histopathology
Histopathology studies of pancreas of STZ induced
diabetic rat displayed reduction of the Islets of Langerhans,
damaged or reduced the size of β cells and extensive
necrosis changes followed by fibrosis and atrophy. STZ
induced diabetic rat treated with different doses of UFD and
glibenclamide restored the necrotic and fibrotic changes
and raised the number of β cells (Figures 23 and 24).
Effect of UFD on heart histopathology
STZ induced diabetic rat showed the increased degree of
interstitial space and distort intercalated disc (Figure 25).
STZ induced diabetic rat, treatment with altered doses
of UFD and glibenclamide showed effect on the heart
histopathology. STZ induced diabetic rat treated with
UFD (10 mg/kg) dose showed less interstitial space
and distort intercalated disc compared to the diabetic




















Figure 17 Effect of UFD on level of GPx (Glutathione peroxidase) cho
compared to standard drug Glibenclamide; values are mean ± SEM; n
non-significant (ns).interstitial space and UFD (40 mg/kg) dose showed
the normal histopathology of heart like glibenclamide
treated group rat (Figure 26). Glibenclamide treated
group exhibited the histopathology like the normal
control.
Discussion
Aegle marmelos Correa rich source of many compounds.
The methanolic extract was subjected to column chroma-
tography and isolated the compound. The isolated
compound exhibited blue fluorescence and UV absorption
maxima at 256, 277 and 332 nm and IR absorption band
at 1702 cm-1 for δ-lactone ring suggested coumarin nature
of the molecule. It also had IR absorption bands for
hydroxyl groups (3452, 3401, 3325 cm-1) and an aromatic
ring (1629, 1515 cm-1). On the basis of mass spectrum
and 13C NMR spectra the molecular ion peak of the
compound was determined at m/z 486 consistent to the
molecular formula of a coumarin diglycoside C21H26O13.
The 1H NMR spectrum showed the presence of two
AB-type doublets at δ 6.83 (J = 9.2 Hz) and 7.47 (J = 9.2 Hz)
assigned to vinylic H-3 and H-4 protons, respectively. ANormal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
lesterol at different concentrations on STZ induced diabetic rats,
= 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
























207.8 ± 1.985 206.6 ± 1.077 71.8 ± 2.691*** 147.8 ± 2.177* 177.8 ± 3.955** 193.2 ± 3.247*** 191.6 ± 2.421***
2 CAT (U/mg
of protein)
135.8 ± 1.855 135.4 ± 2.358 57 ± 1.517*** 79.8 ± 1.985* 100.8 ± 1.934* 122.4 ± 2.015*** 118.8 ± 0.861***
3 GPx (nmole/mg
of protein)
34.4 ± 1.077 34.8 ± 1.241 14 ± 0.707*** 22.4 ± 0.509* 26.4 ± 0.562** 32 ± 0.712*** 29.6 ± 0.514***
4 MDA (nmole/mg
of protein)
0.212 ± 0.008 0.218 ± 0.009 0.526 ± 0.011*** 0.431 ± 0.013* 0.331 ± 0.012** 0.251 ± 0.007*** 0.294 ± 0.005***
All values represent mean ± SEM *P < 0.05; **P < 0.01; ***P < 0.001, ns < non significant; ANOVA, followed by Dunnett’s multiple comparison test.
aCompared to vehicle control.
bCompared to diabetic control.
Kumar et al. SpringerPlus 2013, 2:639 Page 13 of 20
http://www.springerplus.com/content/2/1/639one-proton double doublet at δ 7.55 (J = 9.8, 2.8 Hz) and
two one-proton doublets at δ 7.20 (J = 2.8 Hz) and 6.40 Hz
(J = 9.8 Hz) were ascribed to coumarin H-6, H-8 and H-5
protons, respectively. Two one-proton doublets at δ
5.27 (J = 3.6 Hz) and 4.99 (J = 3.6 Hz) were accounted
to α-oriented anomeric H-1I and H-1II protons, respectively.
The other sugar protons resonated between δ 4.81 – 3.04.
The 13C NMR spectrum displayed signals for nine
coumarin carbons in the range of δ 162.24 – 106.36,
anomeric carbons at δ 103.80 (C-1I), 99.61 (C-1II)
and other sugar carbons between δ 82.31 – 60.72.
The existence of NMR H-2I signal in the deshielded
region at δ 4.31 and carbon C-2I signal at δ 82.31 indi-
cated (2I→ 1II) linkage of the sugar units. The HMBC
spectrum of the coumarin showed interactions of
H-6, H-8 and H-1I with C-7; H-3 and H-4 with C-2;
and H-2I, H-2II and H-3II with C-1II. The 1H and 13C NMR
spectral data of the coumarin nucleus were compared with
the reported data of other coumarins (Rao et al. 2009;
Aslam et al. 2012; Chakthong et al 2012). On the basis of
spectral data analysis the structure of this compound


























Figure 18 Effect of UFD on level of MDA (Malondialdehyde) cholester
compared to standard drug Glibenclamide; values are mean ± SEM; n
non-significant (ns).Diabetes (Type II) generally occurs due to human
genetically susceptibility, as a result loss of insulin producing
pancreatic β-cell cytotoxicity mediated through the release
of nitric oxide (NO). Insulin dependent diabetes mellitus
(IDDM) is caused by the progressive destruction of
the insulin secreting pancreatic β-cells. STZ is a cytotoxic
compound obtained from the soil microbes Streptomyces
achromogenes. STZ mainly penetrate the β-cells via
glucose transporter and break the DNA strand in β-cells
causing the endogenous insulin release (Kumar et al. 2011b).
Due to breakage of DNA strand leads to amendment of
blood sugar level and glucose concentrations in blood.
Several plant have been accounted as an antidiabetic
effect by a variety of mechanisms such as stimulating
the regeneration of Islets of Langerhans in the pancreas,
improving insulin sensitivity and augmenting glucose
dependent insulin secretion in STZ induced diabetic rats
(Sezik et al. 2005; Daisy et al. 2009).
A lot of synthetic antidiabetic drugs available in the
market but sulfonylurea such as glibenclamide often use
as a standard antidiabetic drug in STZ induced diabetes
to compare the efficacy of a variety of antihyperglycemic
compounds. (Kumar et al. 2013a).Normal Control
Normal Control+UFD (40 mg/kg)
Diabetic Control
UFD I (10 mg/kg)
UFD II (20 mg/kg)
UFD III (40 mg/kg)
Glibenclamide (10 mg/kg)
a
ol at different concentrations on STZ induced diabetic rats,
= 6; cP < 0.05; bP < 0.01; aP < 0.001; P > 0.05 is considered as
Figure 19 Effect of UFD on liver in different groups of rats: (A) Normal control: Histopathology of normal control group did not shown
any fat deposition and other changes (B) Diabetic control: Histopathology of diabetic rat showed accumulation of micro droplet of fat
(yellow arrow) (C) UFD I (10 mg/kg): Histopathology of the starting dose of tested drug shown some part having fat deposition which
was less compared to the diabetic control (yellow arrow). (D) UFD II (20 mg/kg): Histopathology of second dose of tested drug showed very
few micro droplet of fat (yellow arrow). (E) UFD III (40 mg/kg): Histopathology of other tested drug not showing any fat deposition and other
changes. (F) Glibenclamide (10 mg/kg): Standard drug treated group shown histopathology similar to the normal control groups. The samples
were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for
each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .
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UFD revealed the non-toxic nature in the lower dose.
There was no lethality or any toxic reactions found with
the selected doses of UFD until the end of the specific
study. The selection of the doses was done on the basis
of calibration curve (Salahuddin and Jalalpure 2010).Figure 20 Effect of UFD on liver in different groups of rats: (A) norma
histopathology. (B) Diabetic control: Diabetic control rat shown fat depos
(10 mg/kg): Tested drug some part showed the deposition of micro drople
drug showed some part of micro droplet of fat deposition (yellow arrow).
glibenclamide treated drug. (F) Glibenclamide (10 mg/kg): Standard drug t
groups. The samples were obtained from the same liver anatomical region
The above picture for each group was chosen randomly from the 80 pictuOral glucose tolerance test was performed for the
identification of the alteration of carbohydrate metabolism
during post glucose administration. The different doses of
the UFD significantly altered the blood glucose level as
compared to the glucose control group rats. The result
suggests that the different doses of the UFD have betterl control: Normal control not showing any change in liver
ition on the liver in the form of micro droplet. (yellow arrow) (C) UFD I
t of fat (yellow arrow). (D) UFD II (20 mg/kg): Histopathology of tested
(E) UFD III (40 mg/kg): Histopathology of tested drug similar to the
reated group shown histopathology similar to the normal control
s. For each group, 6 rats were examined and 80 pictures were taken.
res in this group. Original magnification, 40 × .
Figure 21 Effect of UFD photomicrographs of histological changes in rat pancreas: (A) Normal control: normal histological structure of
rat pancreas showed normal islet (white arrow) (B) Diabetic control: Histopathology of diabetic control rat showed focal necrosis
(yellow arrow) (C) UFD I (10 mg/kg): Histopathology of tested drug rat showed bigger size of islet and focal necrosis (yellow arrow) (D)
UFD II (20 mg/kg): Histopathology of tested drug rat showed focal necrosis (yellow arrow) (E) UFD III (40 mg/kg): Histopathology of
tested drug rat showed normal size of islet (white arrow) (F) Glibenclamide (10 mg/kg): glibenclamide treated rat pancreas showed
normal islet (white arrow). For each group 6 rats were examined and 80 pictures were taken. The above picture for each group was chosen
randomly from the 80 pictures in this group. Original magnification, 10 × .
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http://www.springerplus.com/content/2/1/639glucose utilization capacity. The possible mechanism of
action of the UFD may be due to insulin emission
from the β-cell and improved the glucose transportation and
consumption in the rats (Ceriello 2005: Santiagu et al. 2012).
STZ induced diabetic rat showed the increase level of
the blood glucose and decrease level of the plasma insulin.
STZ destroy the β-cell in the pancreas and increase
the overproduction of glucose and gluconeogenesis.Figure 22 Effect of UFD photomicrographs of histological changes in
rat pancreas showed normal islet (white arrow) (B) Diabetic control: H
(yellow arrow) (C) UFD I (10 mg/kg): Histopathology of tested drug ra
UFD II (20 mg/kg): Histopathology of tested drug rat showed focal ne
tested drug rat showed normal size of islet (white arrow) (F) Glibencl
normal islet (white arrow). For each group 6 rats were examined and 80
randomly from the 80 pictures in this group. Original magnification, 40 × .Gluconeogenesis and overproduction of the glucose is
the prime factor of the hyperglycemia (Latner 1958).
STZ induced diabetic rats treated with the different
doses of the UFD significantly decreased the blood
glucose level and improve the plasma insulin level by
regeneration of the β-cells. The possible mechanism
of action of the UFD may be stimulating the insulin
secretion and regeneration of the β-cells of the pancreasrat pancreas: (A) Normal control: normal histological structure of
istopathology of diabetic control rat showed focal necrosis
t showed bigger size of islet and focal necrosis (yellow arrow) (D)
crosis (yellow arrow) (E) UFD III (40 mg/kg): Histopathology of
amide (10 mg/kg): glibenclamide treated rat pancreas showed
pictures were taken. The above picture for each group was chosen
Figure 23 Effect of UFD photomicrographs of histological on heart in different groups of rats: (A) Normal control: Histopathology of
normal control group rat normal histopathology of heart (B) Diabetic control: Histopathology of diabetic control group rat showed
increased interstitial space and distort the intercalated disc (yellow arrow) (C) UFD I (10 mg/kg): Histopathology of tested drug shown
decreased interstitial space and intercalated disc (yellow arrow) (D) UFD II (20 mg/kg): Histopathology of tested drug showed less
interstitial space (yellow arrow) (E) UFD III (40 mg/kg): Histopathology of tested drug showed normal heart like the glibenclamide (F)
Glibenclamide (10 mg/kg): Histopathology of glibenclamide treated drug shown the normal histopathology of heart. The samples were
obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above picture for each
group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .
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http://www.springerplus.com/content/2/1/639or regeneration of the granules in the β-cells and
enhanced the cellularity of the Islet of Langerhans
(Kumar et al. 2013b). The hypothesis further confirmed by
the pancreas histopathology which showed that the UFD
exhibit the protective effect over the pancreas against theFigure 24 Effect of UFD photomicrographs of histological on heart in
normal control group rat normal histopathology of heart (B) Diabetic
increased interstitial space and distort the intercalated disc (yellow ar
showed decreased interstitial space and intercalated disc (yellow arro
less interstitial space (yellow arrow) (E) UFD III (40 mg/kg): Histopatho
(F) Glibenclamide (10 mg/kg): Histopathology of glibenclamide treate
were obtained from the same liver anatomical regions. For each group, 6 r
each group was chosen randomly from the 80 pictures in this group. Origimicrobial streptozotocin (Figures 23 and 24). The UFD
shows the similar mechanism of action as glibenclamide,
stimulating the insulin secretion.
The decrease in body weight was found throughout
the study in diabetic control group rats. The decrease indifferent groups of rats: (A) Normal control: Histopathology of
control: Histopathology of diabetic control group rat showed
row) (C) UFD I (10 mg/kg): Histopathology of tested drug
w) (D) UFD II (20 mg/kg): Histopathology of tested drug showed
logy of tested drug shown normal heart like the glibenclamide
d drug showed the normal histopathology of heart. The samples
ats were examined and 80 pictures were taken. The above picture for
nal magnification, 40 × .
Figure 25 Effect of UFD on kidney in different groups of rat: (A) Normal control: Normal control histopathology showed normal size of
glomerulus (green arrow) (B) Diabetic control: Histopathology of diabetic control rat showed inflammatory cell in blood vessels
(brown arrow) and deposition of fats (yellow arrow) (C) UFD I (10 mg/kg): Histopathology of tested drug showed inflammation in
blood vessels (brown arrow) and fat deposition (yellow arrow) (D) UFD II (20 mg/kg): Histopathology of tested drug showed only fat
deposition (yellow arrow) (E) UFD III (40 mg/kg): Histopathology of tested drug showed normal kidney histopathology like the
glibenclamide group (F) Glibenclamide (10 mg/kg): Glibenclamide treated animal histopathology shown the normal kidney. The
samples were obtained from the same liver anatomical regions. For each group, 6 rats were examined and 80 pictures were taken. The above
picture for each group was chosen randomly from the 80 pictures in this group. Original magnification, 10 × .
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http://www.springerplus.com/content/2/1/639body weight due to gluconeogenesis, catabolism of proteins
and fats. Catabolism which is directly associated with
the characteristic loss of body weight due to increased
muscle destruction or degradation of structural proteins
(Paulsen 1973; Shirwaikar et al. 2004; Shirwaikar et al. 2006).Figure 26 Effect of UFD on kidney in different groups of rat: (A) Norm
of glomerulus (green arrow) (B) Diabetic control: Diabetic control hist
cell in blood vessels (brown arrow) (C) UFD I (10 mg/kg): Histopathol
arrow) and fat deposition (yellow arrow) (D) UFD II (20 mg/kg): Histop
(yellow arrow) (E) UFD III (40 mg/kg): Histopathology of tested drug s
Glibenclamide (10 mg/kg): Glibenclamide treated animal histopatholo
same liver anatomical regions. For each group, 6 rats were examined and 8
randomly from the 80 pictures in this group. Original magnification, 40 × .In this manuscript, results suggest that STZ induced diabetic
groups rats treated with different doses of UFD significantly
increased the body weight as compared to the diabetic
control group rats in dose dependent manner. The
potential mechanism of action of the UFD showedal control: Normal control histopathology showed average size
opathology showed fat deposition (yellow arrow) inflammatory
ogy of tested drug showed inflammation in blood vessels (brown
athology of tested drug showed fat deposition in few place
howed normal glomerulus but slightly bigger in size (F)
gy shown the normal kidney. The samples were obtained from the
0 pictures were taken. The above picture for each group was chosen
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wasting (reversal of gluconeogenesis).
STZ induced diabetic rats showed the blood glucose
level increased, increase level of glucose, glucose add to
the RBC in N terminal of hemoglobin chain and producing
the glycated hemoglobin (Hba1c) and increased the level of
glycated hemoglobin in STZ induced diabetic rats. In
normal, glycated hemoglobin make up 3.4-5.8% of total
hemoglobin and a small portion of blood glucose, usually
between 4.5-6%, is covalently bonded to the red blood
cells in hemoglobin (Kumar et al. 2013c), but the level of
glycated hemoglobin was increased in diabetic mellitus
patient due to an excess of glucose present in the blood
reacts with hemoglobin to form glycated hemoglobin. The
level of glycated hemoglobin was increased upto 16% in
diabetes mellitus patients (Koeing et al. 1976). Glycated
hemoglobin can be used as an indicator of metallic control
of diabetes since glycohemoglobin levels approach normal
value in diabetes in metabolic control. In this investigation
the level of glycated hemoglobin was elevated more than 4
times to the normal control rats. Treatment with different
doses of UFD significantly brought back the increased
level near normal levels (Table 3), which indicate the
improved level of glycemic control. The possible
mechanism of action of the UFD in the glycated
hemoglobin may be decreasing the blood glucose level and
inhibit the addition of the glucose with the hemoglobin.
Hypercholesterolemia and hypertriglyceridemia are
mostly found in the diabetes due to lipid abnormalities
(Shepherd 2005). These are the major factor involved in
rising of coronary heart disease and atherosclerosis, which
are the secondary complication accompanying during
diabetes (Ananthan et al. 2003). The level of triglyceride
increased due to insulin deficiency resultant failure to acti-
vate lipoprotein lipase thereby causing hypertriglyceridemia
(Shirwaikar et al. 2005). In diabetes, the deposition of the
cholesterol in the peripheral tissue is carrying by LDL and
VLDL, peripheral tissue to survive and then excretion of
cholesterol done by HDL. Hence increased level of LDL
and VLDL is atherogenic. The level of serum lipids was
elevated 2 times more as compared to the normal control
rats. Treatment of different doses of UFD significantly
controls the increased level of serum lipids (Triglyceride,
Low density lipoprotein, VLDL) and significantly increased
the level of HDL in diabetic control rats.
Lately, many investigators have been concentrated
on the role of oxidative stress in diabetes. The inves-
tigator claims that oxidative stress plays an important
role in the development of the diabetic complications
(Sepici-Dinçel et al. 2009). SOD, CAT, GPx plays a signifi-
cant role in preventing the cell damaging from oxidative
stress. During the oxidative stress, production of free radical
starts, once generated, it continuously react to each other
and formed the new free radicals (Kumar et al. 2013c).These free radicals react with all biological substances
(mainly polyunsaturated fatty acids) in the body and
continuous reaction of the free radical lead to lipid
peroxidation. Increased level of lipid peroxidation in
the body decrease the membrane fluidity, change the
membrane bound receptor and impaired enzyme activity of
membrane function (Arulselvan and Subramanian 2007).
In our investigation, the level of SOD, CAT, GPx was
decreased and the level of MDA (as an indicator of LPO)
increased in STZ induced diabetic rats, having high rate of
free radical generation. But treatment with different doses
of UFD significantly decreased the level of MDA. The
decreased in the level of MDA, an increase in the level of
GPx was observed, which led to deactivation of LPO
reaction. ROS (Reactive oxygen species) directly eliminated
by primary enzyme such as SOD and CAT. SOD, is capable
of changing the superoxide radical anions (O2
-) into hydro-
gen peroxide (H2O2) and CAT is capable to the reduction
of hydrogen peroxide and involved in detoxification of
hydrogen peroxide (H2O2) concentration. Some time in
diabetes the level of SOD was increased without increasing
the level of GPx, that in the cell facing the overload of per-
oxidases. Then the cell peroxide reacts with the transitional
metals and immediately formed the hydroxyl radicals,
production of hydroxyl radicals is very harmful to the cells
(Halliwell and Gutteridge 1989). STZ induced diabetes
inactivate the activated antioxidant enzyme such as
SOD, CAT, and GPx by fluctuating these proteins
thus producing induced oxidative stress, continuously oxi-
dative stress caused the LPO (Kennedy and Lyons 1997). In
our investigation the SOD and CAT significantly decreased
the diabetes as a result of non-enzymatic glycosylation and
oxidation (Al-Azzawie and Alhamdani 2006). The possible
mechanism of action of the UFD may be enhancing the
level of the endogenous antioxidant enzymes.
Liver is vital organ that play an important role in defense
of the postprandial hyperglycemia and involved in the
glucose metabolism (synthesis of glycogen). In liver,
glucose is converted into glucose-6-phosphatase by the help
of hexokinase (Latha and Pari 2003; Baquer et al. 1998).
STZ induced diabetic rats decrease glycolysis, disturb the
capacity of the liver to synthesize glycogen and decreased
the level of hexokinase. Decreased level of hexokinase
showed, an effect on glycolysis and inhibits the utilization
of glucose for energy production (Raju et al. 2001).
The STZ induced diabetic rats treated with different
doses of UFD brought back the activity of this enzyme
near to normal control and increases the utilization of
glucose for energy conversion. Another liver vital enzyme
is glucose-6-phosphatase which regulates the glucose
metabolizing enzyme. In STZ induced diabetic rats increased
level of glucose-6-phosphatase boost the production
of fats from carbohydrates and increased the fats deposition
in the liver and kidney (Liu et al. 1994). Some investigators
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enhanced the activity of a gluconeogenetic enzyme
(Bopanna et al. 1997). STZ induced diabetic rats treated
with different doses of UFD had brought back the activity
of glucose-6-phosphatase enzyme near to normal control.
Fructose-1-6-biphosphate is the vital enzyme of the liver
plays an important role in the glycolysis, its convert glu-
cose into the energy (Gold 1970). STZ induced diabetic
rats increased the level of fructose-1-6-biphosphate. Three
different doses of UFD decreased the level of fructose-1-6-
biphosphate near the normal control rats.
Conclusion
Consequently, our research exertion clearly depicts the
beneficial effects of umbelliferon-α-D-glucopyranosyl-
(2I→ 1II)-α-D-glucopyranoside in the STZ induced
diabetic rats. Furthermore, the research is in process
in our laboratory to explicate the exact mechanism of
action of umbelliferon-α-D-glucopyranosyl-(2I→ 1II)-α-
D-glucopyranoside at molecular level.
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